查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534917

慢性阻塞性肺病：市场洞察、流行病学和预测（2024-2032F）

Chronic Obstructive Pulmonary Disease - Market Insight, Epidemiology, & Forecast (2024-2032F)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 155 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

在预测期（2024-2032年），慢性阻塞性肺病市场预计将成长约 5%。新疗法和治疗方法的监管批准数量不断增加是慢性阻塞性肺病市场的关键驱动因素。这些批准反映了医学研究的进步和对该疾病更深入的了解，导致更有效和更有针对性的治疗方法的发展。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构加快审批流程，使患者能够更快地获得创新治疗，改善疾病控制和患者治疗结果。例如，2021年2月，欧洲药品管理局批准 Trixeo Aerosphere (formoterol fumarate/glycopyrronium/budesonide)作为慢性阻塞性肺病的维持治疗。这种三重疗法结合了 LABA、LAMA 和吸入性皮质类固醇（ICS）。

根据已上市治疗药物，市场分为 Symbicort、Dupixent、Dalirecept 等。 Symbicort 细分市场将在2023年占据主要市场占有率。 Symbicort 是一种含有budesonide和formoterol的复合式吸入药物，在慢性阻塞性肺病（COPD）的治疗中发挥重要作用。budesonide是一种皮质类固醇，可减少气道炎症，formoterol是一种长效 β 受体促效剂（LABA），可放鬆气道周围的肌肉，改善呼吸。这种双重作用机制使 Symbicort 能够抑制症状并降低 COPD 恶化的频率。

为了更了解慢性阻塞性肺病市场介绍，根据 7MM 在美国、德国、英国、法国、义大利、西班牙和日本等国家的存在情况对市场进行了分析。到2023年，美国将占据压倒性的市场占有率。由于慢性阻塞性肺病（COPD）的高盛行率和沈重的医疗负担，美国的慢性阻塞性肺病（COPD）市场规模相当大。根据美国疾病管制与预防中心（CDC）的资料，大约有 1,600 万美国人被诊断出患有慢性阻塞性肺病，还有数百万人可能未被诊断出来。慢性阻塞性肺病是导致残疾的主要原因，它降低了受影响者的生活品质，并透过医疗保健费用和生产力下降造成了巨大的经济负担。根据 CDC 报告，慢性阻塞性肺病每年造成约 499亿美元的医疗费用和生产力损失。

市场主要参与者包括AstraZeneca、GSK plc、Boehringer Ingelheim International GmbH、Sanofi、Regeneron Pharmaceuticals Inc.、Inmunotek、Novartis AG、Pulmotect, Inc、Amgen Inc.、Verona Pharma plc等。

目录

第1章 市场介绍

  • 市场定义
  • 主要目的
  • 利害关係人
  • 限制

第2章 研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第3章 执行摘要

  • 行业概况
  • 依细分市场进行预测
    • 市场成长强度
  • 区域展望

第4章 市场动态

  • 促进因素
  • 机会
  • 抑制因素
  • 趋势

第5章 疾病背景与概论

  • 简介
  • 慢性阻塞性肺病的类型
  • 原因
  • 风险因素
  • 基因遗传
  • 病因学
  • 预后
  • 征兆和症状
  • 诊断
    • 诊断标准
    • 鑑别诊断

第6章 治疗

  • 第一线治疗 - 支气管扩张剂
    • 长效 β 受体促效剂（LABA）
    • 短效毒蕈碱拮抗剂（SAMA）
    • 长效毒蕈碱拮抗剂（LAMA）
  • 组合吸入器
    • LABA + LAMA
    • LABA+吸入性皮质类固醇（ICS）
    • 三联疗法（LABA+LAMA+ICS）
  • 吸入性皮质类固醇
  • 磷酸二酯酶 4 抑制剂
  • 黏液溶解剂和抗氧化剂
  • 抗生素
  • 氧气治疗
  • 手术和介入治疗
    • 肺部减容手术（LVRS）
    • 支气管镜肺减容术（BLVR）
    • 肺移植
  • 新疗法
    • 生物疗法
    • 基因治疗
    • 以微生物组为基础的疗法
    • 疫苗

第7章 病人旅程

第8章 流行病学与病患群体，2022-2032F

  • 假设和证据
  • 7MM慢性阻塞性肺病流行病学
    • 7MM中慢性阻塞性肺病患者总数
    • 7MM 中按年龄划分的慢性阻塞性肺病盛行率
    • 7MM 中按性别划分的慢性阻塞性肺病盛行率

第9章 各国慢性阻塞性肺病的流行病学

  • 美国
    • 美国患有慢性阻塞性肺病的总人数
    • 美国按年龄划分的慢性阻塞性肺病盛行率
    • 美国依性别区分的慢性阻塞性肺病盛行率
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 日本

第10章 慢性阻塞性肺病市场洞察、市售治疗方法

  • Symbicort（Dupilumab与Roflumilast）：Allergan plc
    • 药物简介
    • 监理结果
    • 其他开发活动
    • 临床开发
    • 安全性和有效性
  • Dupixent（Dupilumab）：Regeneron Pharmaceuticals/Sanofi
  • Dariresp（Roflumilast）：Allergan plc

第11章 慢性阻塞性肺病市场洞察、新疗法

  • Itepekimab（SAR440340/REGN3500/Anti-IL-33 mAb）：Sanofi/Regeneron
    • 药物简介
    • 临床开发
    • 安全性和有效性
  • Fasenra（Benralizumab）：AstraZeneca
  • Ensifentrine：Verona Pharma plc

第12章 慢性阻塞性肺病市场：7MM分析

  • 主要发现
  • 2022-2032年 7MM 期间慢性阻塞性肺病的总市场规模
  • 慢性阻塞性肺病已上市治疗药物市场规模7MM
  • 以新兴治疗方法划分的慢性阻塞性肺病市场规模 7MM
  • 美国市场规模，2022-2032年
    • 美国慢性阻塞性肺病的总市场规模
    • 美国已上市治疗药物的慢性阻塞性肺病市场规模
    • 美国新兴治疗方法的慢性阻塞性肺病市场规模
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 日本

第13章 未满足的需求

第14章 竞争态势

  • 主要竞争对手 - 上市疗法
  • 主要竞争对手 - III 期药品
  • 主要竞争对手 - II 期药品

第15章 公司简介

  • AstraZeneca
    • 公司概况
    • 主要财务资料
    • SWOT分析
    • 产品组合
    • 近期动态
  • GSK plc
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Regeneron Pharmaceuticals Inc.
  • Inmunotek
  • Novartis AG
  • Pulmotect, Inc.
  • Amgen Inc.
  • Verona Pharma plc

第16章 缩写与假设

第17章 附录

简介目录
Product Code: UMHE212916

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation, primarily due to significant exposure to noxious particles or gases. It encompasses conditions like emphysema and chronic bronchitis, where inflammation and structural changes in the airways lead to narrowed air passages and reduced airflow. COPD is a major cause of morbidity and mortality globally, affecting over 65 million people and causing approximately 3 million deaths annually.

The Chronic Obstructive Pulmonary Disease Market is expected to grow around ~5% during the forecast period (2024-2032). The increasing number of regulatory approvals for new treatments and therapies is a significant driver in the COPD market. These approvals reflect advancements in medical research and a better understanding of the disease, which lead to the development of more effective and targeted therapies. The accelerated approval process by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) allows patients to access innovative treatments more quickly, improving disease management and patient outcomes. For instance, in February 2021, Europe Medicines Agency approved Trixeo Aerosphere (formoterol fumarate/glycopyrronium/budesonide) for the maintenance treatment of COPD. This triple therapy combines a LABA, a LAMA, and an inhaled corticosteroid (ICS).

Based on the marketed therapies, the market has been divided into Symbicort, Dupixent, Dalirespt, and others. Symbicort segment held a significant market share in 2023. Symbicort, a combination inhaler containing budesonide and formoterol, plays a significant role in the management of Chronic Obstructive Pulmonary Disease (COPD). Budesonide, a corticosteroid, reduces inflammation in the airways, while formoterol, a long-acting beta-agonist (LABA), helps relax the muscles around the airways to improve breathing. This dual-action mechanism makes Symbicort effective in both controlling symptoms and reducing the frequency of COPD exacerbations.

For a better understanding of the market adoption of Chronic Obstructive Pulmonary Disease, the market is analyzed based on its 7MM presence in countries such as The United States, Germany, UK, France, Italy, Spain, Japan. The United States held a dominant share of the market in 2023. The U.S. market for Chronic Obstructive Pulmonary Disease (COPD) is substantial, driven by the high prevalence and significant healthcare burden of the disease. According to the Centers for Disease Control and Prevention (CDC), approximately 16 million Americans are diagnosed with COPD, and millions more are likely undiagnosed. COPD is a leading cause of disability, reducing the quality of life for those affected and imposing a significant economic burden due to healthcare costs and lost productivity. The CDC reports that COPD costs the nation approximately $49.9 billion annually in healthcare expenditures and lost productivity.

Some of the major players operating in the market include AstraZeneca; GSK plc; Boehringer Ingelheim International GmbH; Sanofi; Regeneron Pharmaceuticals Inc.; Inmunotek; Novartis AG; Pulmotect, Inc; Amgen Inc.; and Verona Pharma plc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Chronic Obstructive Pulmonary Disease Market
  • 2.2. Research Methodology of the Chronic Obstructive Pulmonary Disease Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends

5.DISEASE BACKGROUND AND OVERVIEW

  • 5.1. Introduction
  • 5.2. Types of COPD
  • 5.3. Causes
  • 5.4. Risk Factors
  • 5.5. Genetic Inheritance
  • 5.6. Pathogenesis
  • 5.7. Prognosis
  • 5.8. Signs and Symptoms
  • 5.9. Diagnosis
    • 5.9.1. Diagnosis Criteria
    • 5.9.2. Differential Diagnosis

6.TREATMENT

  • 6.1. First Line Treatment - Bronchodilators
    • 6.1.1. Long-Acting Beta Agonists (LABAs)
    • 6.1.2. Short-Acting Muscarinic Antagonists (SAMAs)
    • 6.1.3. Long-Acting Muscarinic Antagonists (LAMAs)
  • 6.2. Combination Inhalers
    • 6.2.1. LABA + LAMA
    • 6.2.2. LABA + Inhaled Corticosteroids (ICS)
    • 6.2.3. Triple Therapy (LABA + LAMA + ICS)
  • 6.3. Inhaled Corticosteroids
  • 6.4. Phosphodiesterase-4 Inhibitors
  • 6.5. Mucolytics and Antioxidants
  • 6.6. Antibiotics
  • 6.7. Oxygen Therapy
  • 6.8. Surgical and Interventional Therapies
    • 6.8.1. Lung Volume Reduction Surgery (LVRS)
    • 6.8.2. Bronchoscopic Lung Volume Reduction (BLVR)
    • 6.8.3. Lung Transplant
  • 6.9. Emerging Therapies
    • 6.9.1. Biologic Therapy
    • 6.9.2. Gene Therapy
    • 6.9.3. Microbiome-Based Therapies
    • 6.9.4. Vaccines

7.PATIENT JOURNEY

8.EPIDEMIOLOGY & PATIENT POPULATION, 2022-2032F

  • 8.1. Assumptions and Rationale
  • 8.2. Epidemiology of Chronic Obstructive Pulmonary Disease in 7MM
    • 8.2.1. Total Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM
    • 8.2.2. Age-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM
    • 8.2.3. Gender-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM

9.EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY COUNTRY

  • 9.1. The United States
    • 9.1.1. Total Prevalent Population of Chronic Obstructive Pulmonary Disease in the United States
    • 9.1.2. Age-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the United States
    • 9.1.3. Gender-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the United States
  • 9.2. Germany
  • 9.3. UK
  • 9.4. France
  • 9.5. Italy
  • 9.6. Spain
  • 9.7. Japan

10.CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET INSIGHTS, MARKETED THERAPIES

  • 10.1. Symbicort (Budesonide and Formoterol): AstraZeneca
    • 10.1.1. Drug Profile
    • 10.1.2. Regulatory Achievements
    • 10.1.3. Other Development Activities
    • 10.1.4. Clinical Development
    • 10.1.5. Safety and Efficacy
  • 10.2. Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi
  • 10.3. Daliresp (Roflumilast): Allergan plc

11.CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET INSIGHTS, EMERGING THERAPIES

  • 11.1. Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals
    • 11.1.1. Drug Profile
    • 11.1.2. Clinical Development
    • 11.1.3. Safety and Efficacy
  • 11.2. Fasenra (Benralizumab): AstraZeneca
  • 11.3. Ensifentrine: Verona Pharma plc

12.CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET: 7MM ANALYSIS

  • 12.1. Key Findings
  • 12.2. Total Market Size of Chronic Obstructive Pulmonary Disease in the 7MM, 2022-2032F
  • 12.3. Market Size of Chronic Obstructive Pulmonary Disease by Marketed Therapies in the 7MM
  • 12.4. Market Size of Chronic Obstructive Pulmonary Disease by Emerging Therapies in the 7MM
  • 12.5. United States Market Size, 2022-2032F
    • 12.5.1. Total Market Size of Chronic Obstructive Pulmonary Disease in the United States
    • 12.5.2. Market Size of Chronic Obstructive Pulmonary Disease by Marketed Therapies in the United States
    • 12.5.3. Market Size of Chronic Obstructive Pulmonary Disease by Emerging Therapies in the United States
  • 12.6. Germany
  • 12.7. UK
  • 12.8. France
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. Japan

13.UNMET NEEDS

14.COMPETITIVE LANDSCAPE

  • 14.1. Key Competitors - Marketed Therapies
  • 14.2. Key Competitors - Phase III Drugs
  • 14.3. Key Competitors - Phase II Drugs

15.COMPANY PROFILES

  • 15.1. AstraZeneca
    • 15.1.1. Company Overview
    • 15.1.2. Key Financials
    • 15.1.3. SWOT Analysis
    • 15.1.4. Product Portfolio
    • 15.1.5. Recent Developments
  • 15.2. GSK plc
  • 15.3. Boehringer Ingelheim International GmbH
  • 15.4. Sanofi
  • 15.5. Regeneron Pharmaceuticals Inc.
  • 15.6. Inmunotek
  • 15.7. Novartis AG
  • 15.8. Pulmotect, Inc.
  • 15.9. Amgen Inc.
  • 15.10. Verona Pharma plc

16.ACRONYMS & ASSUMPTION

17.ANNEXURE